Management of Cardiovascular Risk Factors

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00848380
First received: February 19, 2009
Last updated: November 15, 2010
Last verified: November 2010
  Purpose

This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia


Condition
Cardiovascular Risk Factors
Cardiovascular Diseases

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Management of Cardiovascular Risk Factors

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. [ Time Frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit ] [ Designated as safety issue: No ]

Enrollment: 1492
Study Start Date: February 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with hypertension and hyperlipidemia and other CV risk factors

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients with hypertension and hyperlipidemia and other CV risk factors

Criteria

Inclusion Criteria:

  • Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
  • Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
  • Patients received during the observation time new cholesterol lowering and hypertension treatment

Exclusion Criteria:

  • Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00848380

Locations
Switzerland
Research Site
Frick, AG, Switzerland
Research Site
Neuenhof, AG, Switzerland
Research Site
Thun, BE, Switzerland
Research Site
Wynigen, BE, Switzerland
Research Site
Riehen, BS, Switzerland
Research Site
Geneve, GE, Switzerland
Research Site
Le Lignon, GE, Switzerland
Research Site
Meyrin, GE, Switzerland
Research Site
Andeer, GR, Switzerland
Research Site
Ilanz, GR, Switzerland
Research Site
Rorschach, SG, Switzerland
Research Site
St. Gallen, SG, Switzerland
Research Site
Gerlafingen, SO, Switzerland
Research Site
Lohn SO, SO, Switzerland
Research Site
Zuchwil, SO, Switzerland
Research Site
Schwyz, SZ, Switzerland
Research Site
Arbedo, TI, Switzerland
Research Site
Bellinzona, TI, Switzerland
Research Site
Claro, TI, Switzerland
Research Site
Coldrerio, TI, Switzerland
Research Site
Locarno, TI, Switzerland
Research Site
Lugano, TI, Switzerland
Research Site
Muralto, TI, Switzerland
Research Site
Bassins, VD, Switzerland
Research Site
Gland, VD, Switzerland
Research Site
Lausanne, VD, Switzerland
Research Site
Montreux, VD, Switzerland
Research Site
Nyon, VD, Switzerland
Research Site
Zug, ZG, Switzerland
Research Site
Affoltern am Albis, ZH, Switzerland
Research Site
Feldmeilen, ZH, Switzerland
Research Site
Herrliberg, ZH, Switzerland
Research Site
Langnau am Albis, ZH, Switzerland
Research Site
Richterswil, ZH, Switzerland
Research Site
Ruti ZH, ZH, Switzerland
Research Site
Zurich, ZH, Switzerland
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: Dr. Dirk Schneider , Medical Affairs & Regulatory Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00848380     History of Changes
Other Study ID Numbers: NIS-CCH-DUM-2008/2
Study First Received: February 19, 2009
Last Updated: November 15, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
Hypertension
hyperlipidemia

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 20, 2014